Breaking News
Letters to the editor

340B needs transparency

2 min read

Dick Harris

Stevensville, Pa.

I appreciate the Trump administration for recognizing the need for increased accountability and transparency in the 340B Drug Pricing Program.

The 340B program was created to help ensure low-income and rural patients have access to affordable medicines. It's an important mission and worth protecting. But no program is so important that policymakers and taxpayers shouldn't ask questions about how it operates.

The administration's rebate pilot offers a reasonable way to strengthen oversight. For selected medicines, providers would receive the 340B discount through a rebate after submitting transaction information. The goal is to verify eligible purchases and help prevent duplicate discounts.

I don't believe that transparency is a threat to the 340B program. If anything, I think increased transparency would strengthen confidence in the program and protect it for the future.

Taxpayers deserve responsible oversight of federal healthcare programs, especially those that have grown significantly. Patients also deserve confidence that programs intended to support their care are accountable.

Of course, it makes sense that the pilot should be implemented carefully and evaluated to understand its effects on patients and safety-net providers. Its success should mean stronger oversight while preserving patient access to care.

The Trump administration deserves credit for pursuing a more transparent approach. If we want 340B to be there for future patients, we should also want to know it’s working the way Congress intended.

Starting at /week.